Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Conditions

• Clinically Significant Prostate Cancer

Eligibility Criteria

Sex

MALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Key Dates

Start date

Mar 12, 2021

Status verified

Mar 2026

Primary completion

Dec 31, 2026

Completion

Jun 30, 2027

Study Design

Enrollment

1,700 participants (estimated)

Arms

• Arm: Study Cohort
  The experimental arm receiving diagnosis from serum RNA combination

Primary Outcome Measure

The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa [ Time Frame: The time of prostate biopsy ]

Central Contacts

• Jianhua Jiao, MD.
  +86 029 84771062
  [email protected]

Locations (1)

Find similar trials in Chicago, IL